Factors that Predict HPV Vaccination Behavior Among Young Men-Who-Have-Sex-with-Men in the Greater Philadelphia Region

Tyrell Mann-Barnes1,2 · Aisha Bhimla1 · Michael Coronado1 · Timmy Lin1 · Adebola Duro-Aina1 · Hemi Park1 · Grace X. Ma1,3

Received: 13 April 2022 / Revised: 14 August 2022 / Accepted: 17 August 2022 / Published online: 29 August 2022
© W. Montague Cobb-NMA Health Institute 2022

Abstract
Human papillomavirus (HPV) is one of the most common sexually transmitted infections in the USA. HPV is acknowledged as one of the leading causes of anal cancer, with an increased risk in men who have sex with men (MSM), when compared to age-matched heterosexual men. This study highlights the various factors that influence and impede HPV vaccination uptake among a multiracial cohort of young-MSM (YMSM). A total of 444 participants aged 18 to 27 in the Greater Philadelphia region completed an online survey. Approximately 75.79% (n = 335) of participants did not receive at least one dose of the HPV vaccine. Having a healthcare provider recommendation (OR = 25.54, 95% CI: 25.54–85.42, p < 0.001) and a one unit increase in experiences of adverse effects of stigma and homophobia (OR = 1.06, 95% CI: 1.01–1.11, p = 0.044) were associated with a greater likelihood of receiving the HPV vaccine uptake. Having a greater number of sexual partners (OR = 0.85, 95% CI: 0.75–0.97, p = 0.014) and having had condomless anal sex in the past 6 months (OR = 0.31, 95% CI: 0.15–0.58, p < 0.001) were associated with a lower odds of HPV vaccine uptake. In conclusion, healthcare provider-focused interventions and educational programs are needed to increase awareness and uptake of the HPV vaccine to mitigate the risks associated with sexual behaviors among this population.

Keywords Human papillomavirus · Sexually transmitted infections

Introduction
Human papillomavirus (HPV) is the most common sexually transmitted infections (STI) in the USA [1]. Although a majority of HPV infections are transient, persistent HPV infection is associated with an increased risk of cancer. Specifically, HPV infection accounts for the development of more than 90% of anal and cervical cancers, more than 70% of oropharyngeal and vaginal cancers, and more than 60% of vulvar and penile cancers [1–4]. Although there are over 100 different genetic variations and HPV serotypes, 16 and 18 are considered to be the most common and most high-risk for cancer development [3, 5, 6]. HPV disproportionately affects men-who-have-sex-with-men (MSM), in whom the prevalence has been reported to be as high as 60% [6].

Approximately 50% of those infections are caused by high-risk HPV types [7–10]. General major risk factors for contraction of HPV include engaging in high-risk sexual behaviors, such as early sexual debut and having multiple sexual partners, and unprotected sexual intercourse [7–9]. Furthermore, MSM have an increased chance of contracting high-risk HPV compared to heterosexual men due to engaging in sexual practices such as receptive anal intercourse [11–13].

Prevention of new HPV infection is accomplished through HPV vaccination. In the USA, Gardasil, a 9-valent HPV vaccine, is the only HPV vaccine currently distributed for use [14]. This vaccine confers protection against nine of the aforementioned high-risk HPV serotypes [14]. HPV vaccines are administered in a three-dose series to individuals 15 to 45 years old who initiate vaccination. The schedule of three doses is 0, 1 to 2 months, and 6 to 12 months, respectively. At present, the Advisory Committee on Immunization Practices (ACIP) recommends vaccination for all children and adults ages 9 through 26 years and catch-up vaccination for all individuals up to age 26 [15]. Despite current ACIP
recommendations, young men who have sex with men (YMSM), ages 18–26, remain largely unvaccinated [16–18]. In a recent national study, the data displayed that only 6.8% of YMSM had received one dose or more of the HPV vaccine [7, 18]. Although this vaccination rate is an improvement in past years, there are still many YMSM that remain unvaccinated.

Numerous factors act as barriers to obtaining the HPV vaccination among MSM including psychosocial and healthcare-driven factors. Healthcare access-related barriers include cost, fear of needles, physician non-recommendation, and accessibility of primary care [19–21]. Only 4% of unvaccinated YMSM were recommended the vaccine by their primary care provider [7]. Individual-level barriers to HPV vaccination and screening include stigma, lack of knowledge, and inconsistent access to healthcare [14, 19, 22]. For MSM, this stigma is largely associated with sexuality, historical contextualization of gay health, and STI health [22]. Stigma may result in the increased likelihood of primary care avoidance or postponement of healthcare visits and decreased sense of self-efficacy [19, 22]. In addition to the aforementioned barriers to HPV vaccination and screening in MSM, YMSM experience additional individual-level barriers. These include being uninsured or insured under their parents and fear that either HPV screening or vaccination will show up on a medical bill [7]. Furthermore, another significant barrier is a lack of knowledge and awareness of HPV and its association with the potential development of cancer among MSM [20, 22, 23]. The aforementioned overall positive attitudes regarding vaccines, in general, are correlated with increased awareness and knowledge of the HPV vaccine [20, 22]. Studies indicate that MSM have expressed that with increased recommendation and education regarding the HPV vaccine, they would accept the vaccine [7, 20, 23]. In addition, self-efficacy has been shown to be associated with higher rates of reported vaccination and increased intention to become vaccinated against HPV [17, 24].

Limited research has been conducted on the YMSM population regarding HPV vaccination and perspectives, particularly with relation to ethnic minorities. Throughout the existing literature, there are few reports that focus on YMSM, and of those studies, many samples consist largely of non-Hispanic White males. Further research is required to understand the barriers to HPV vaccination and screening among YMSM. The current study addresses this critical gap in the literature. The aim of this study was to assess psychosocial, sexual behavioral, and healthcare factors that influence HPV vaccination uptake among YMSM.

Methods

Participants and Sample

Participants were recruited and subsequently enrolled from community-based organizations (CBOs), social media (including LGBTQ Facebook groups), and university LBGTQ student organizations in the Greater Philadelphia region. Recruitment was accomplished through active engagement with CBO leaders, volunteers, online flyers, participant-driven referrals, and online ad placements. Institutional Review Board (IRB) approval was obtained for the study. Participants were recruited from September 2020 to January 2021 to participate in this cross-sectional study, which was administered online via Qualtrics. Participants were eligible to participate in this study if they: (1) were between 18 and 27 years of age; (2) self-identified as a man; (3) self-reported having sex with men in their lifetime (oral, anal, or both); (4) lived in the Greater Philadelphia region; and (5) were able to complete the survey in English. Participants who completed the survey received a $20 gift card. A total of 2137 participants accessed the online Qualtrics survey, and after screening for eligibility a total of 444 participants were eligible to participate and were included in this study data sample for analysis. Reasons for ineligibility included that they were not between the ages of 18–27, did not self-identify as a man, reported not having sex with men in their lifetime, or did not live in the Greater Philadelphia region and thus did not move further in completing the survey.

Measures

The online survey was used to capture self-reported data and all data was collected at a single time point for each participant. Metrics were selected for inclusion in the analysis based on the factors that were relevant and associated with HPV vaccination, as underlined in the preliminary literature review. The survey was developed in Qualtrics and contained the following sections:

Demographic variables (7 items)—Information on age, race/ethnicity, income, marital status, employment status, level of education, and housing security (experienced homelessness) was collected.

Gender and sexual orientation (2 items)—Information on gender and sexual identity and orientation was collected using Haupert’s inclusive gender identity measure [24, 25]. Gender identity was included in the eligibility criteria; thus, 100% of participants identified as male.

Sexual behaviors (12 items)—Information on sexual debut, number of sexual partners in the past 6 months, and having had condomless anal sex in the past month was collected [24, 25].

Healthcare factors (3 items)—Information about healthcare included whether the participant had health insurance, had a healthcare provider they visited, and whether a healthcare professional ever recommended the HPV vaccine.
HPV vaccination history (9 items)—Information on HPV vaccination, type of vaccination received, number of doses received, and location of vaccine administration was collected. The rationale for not receiving the HPV vaccine in unvaccinated participants and barriers to receiving the HPV vaccine in vaccinated participants were collected through a series of 12 statements and a 6-point Likert scale, ranging from strongly disagree to strongly agree. Participants were asked “Have you ever received the HPV vaccination (at least one dose)” with responses yes and no.

Knowledge about HPV (14 items)—Knowledge of HPV symptoms and perceptions of HPV risk were collected from participants. The first item required participants to identify the various symptoms that HPV may cause. This used a series of 13 statements accompanied by a 5-point Likert scale, ranging from “strongly disagree” to “strongly agree.” to identify participant knowledge regarding HPV. Knowledge regarding HPV transmission and attitudes toward HPV prevention strategies were collected. A 10-point Likert scale was used to evaluate participants’ knowledge of HPV prevention strategies. This section was adapted from a study by Forster et al. and Wheldon et al. [21, 26]. Items were summed with a maximum score of 75.

Adverse effects of stigma and homophobia (15 items)—Information regarding participant beliefs toward sexual orientation, fear of coming out, and perceived gay-related stigma was collected using a series of 15 statements and a 5-point Likert scale, which ranged from “strongly disagree” to “strongly agree.” The items from this section were adapted from the measures and investigator-adapted scale in a study on internalized homophobia and perceived stigma by Puckett et al. [26]. Items were summed with a minimum score of 5 and a maximum score of 75.

Perceived risk of becoming infected with HPV (6 items)—Information on one’s risk of being infected with HPV was collected through 6 items on a five-point Likert scale ranging from very unlikely (0) to very likely (5). Items were summed with a maximum score of 30.

Attitudes toward HPV vaccination (9 items)—Information regarding participants’ attitudes toward receiving an HPV vaccination was collected through the 9 items in this section. Both items consisted of a series of statements accompanied by a 5-point Likert scale with a maximum score of 45.

Data Analysis

The study measures were descriptively summarized using means and standard deviations for continuous variables and frequencies and percentages for categorical variables, and bivariate analyses were presented by examining categorical and continuous variables by vaccination status. Factors that were significant in the bivariate analyses were included in the logistic regression model. We ran a multicollinearity test to determine whether there were any variables in our model that were highly correlated with each other. There was no multicollinearity based on the tolerance, variance inflation, eigenvalues; thus, there were no threats to the assumptions for the regression model. Multivariable logistic regression was utilized to examine associations between sociodemographic/healthcare factors, HPV-related knowledge, sexual behaviors, and HPV vaccination. All hypothesis tests were two-tailed and p values less than 0.05 were considered statistically significant. All analyses were conducted in SAS 9.4.

Results

Descriptive Characteristics of Study Participants

The mean age of study participants was 23.1 years, with 65.90% identifying as non-Hispanic White, followed by non-Hispanic Black (14.87%), Hispanic/Latino (14.19%), and non-Hispanic other (5.03%). The majority of participants had completed some university level (54.18%) or high school/GED (42.21%). Most participants (85.81%) were currently employed, and more than half (65.16%) of participants made less than $40,000 per year. In terms of housing security, 34.84% of participants experienced homelessness in the past. Most participants identified as gay (78.60%) and more than half of the study sample (61.5%) were not currently married or in a relationship, characterized as single, divorced, or widowed. In terms of healthcare characteristics, 93.86% of participants had health insurance, and 87.47% had a primary health care provider they visited, and 65% were recommended the vaccine by a health care provider. There were significant differences in income (p < 0.0001), sexual orientation (p = 0.0296), marital status (p = 0.0011), and healthcare provider recommendation (<0.001) by vaccination status. These findings are displayed in Table 1.

Characteristics of Sexual Behaviors and Psychosocial Factors by HPV Vaccination Status

The mean number of sexual partners in the past 6 months was 2.5 (± 2.4) and the mean age of sexual debut was 17.78 (± 1.92) years. Among the total sample, almost half of the participants reported having condomless anal sex in the past month. There were statistically significant differences in the number of sexual partners (p < 0.0001) and age at sexual debut (p < 0.0001) by vaccination status in the bivariate analysis. Furthermore, in terms of
psychosocial factors, the total knowledge score was 44.36 (± 6.6), perceived risk of contracting HPV was 13.02 (± 2.26), attitudes toward HPV and the vaccine was 27.87 (± 3.81), and experiences of stigma and homophobia were 48.45 (± 6.68). There were statistically significant differences in HPV-related knowledge ($p = 0.0008$), perceived risk of contracting HPV ($p = 0.0361$), and experiences of stigma and homophobia ($p = 0.0002$) by vaccination status in the bivariate analysis. Results are illustrated in Table 2.

### Table 1 Descriptive statistics of study participants by HPV vaccination status

| Variable                          | Vaccination status | Total n (%)/mean (SD) | p value |
|-----------------------------------|--------------------|-----------------------|--------|
|                                   | Yes n (%)/mean (SD)| No n (%)/mean (SD)    |        |
| Age                               | 22.86 (2.19)       | 23.17 (2.13)          | 0.6963 |
| Race/ethnicity                    |                    |                       |        |
| Non-Hispanic Black                | 11 (17.19)         | 53 (82.81)            | 0.5103 |
| Non-Hispanic White                | 71 (24.65)         | 217 (75.35)           |        |
| Non-Hispanic other                | 6 (27.27)          | 16 (72.73)            |        |
| Hispanic/Latino                   | 17 (27.87)         | 44 (72.13)            |        |
| Education                         |                    |                       |        |
| < High school                     | 4 (26.67)          | 11 (73.33)            | 0.1696 |
| High school/GED                   | 37 (19.79)         | 150 (80.21)           |        |
| ≥ University                      | 66 (27.62)         | 173 (72.38)           |        |
| Employment status                 |                    |                       |        |
| Currently employed                | 87 (23.26)         | 287 (76.74)           | 0.2466 |
| Not currently employed            | 20 (29.85)         | 47 (70.15)            |        |
| Income                            |                    |                       |        |
| <$40,000 per year                 | 87 (30.21)         | 201 (69.79)           | < 0.0001|
| ≥ $40,000 per year                | 20 (12.99)         | 134 (87.01)           |        |
| Experienced homelessness          |                    |                       |        |
| Yes                               | 42 (27.27)         | 112 (72.73)           | 0.2714 |
| No                                | 65 (22.57)         | 223 (77.43)           |        |
| Sexual orientation                |                    |                       |        |
| Gay                               | 84 (24.21)         | 263 (75.79)           | 0.0296 |
| Bisexual                          | 13 (17.81)         | 60 (82.19)            |        |
| Heterosexual                      | 10 (45.45)         | 12 (54.55)            |        |
| Marital status                    |                    |                       |        |
| Single/divorced/widowed           | 51 (18.89)         | 219 (81.11)           | 0.0011 |
| In a relationship/married         | 55 (32.54)         | 114 (67.46)           |        |
| Insurance                         |                    |                       |        |
| Not insured                       | 6 (23.08)          | 20 (76.92)            | 0.8955 |
| Insured                           | 100 (24.21)        | 313 (75.79)           |        |
| Health care provider              |                    |                       |        |
| Yes                               | 93 (24.28)         | 290 (75.72)           | 0.9167 |
| No                                | 13 (23.64)         | 42 (76.36)            |        |
| Health care provider recommendation|                    |                       |        |
| Yes                               | 104 (35.99)        | 185 (64.01)           | < 0.001|
| No                                | 3 (1.97)           | 149 (98.03)           |        |

Bolded values are significance of $p < 0.05$

Multiple Logistic Regression as Predictors of HPV Vaccination History

The logistic regression analysis showed that having a healthcare provider recommendation (OR = 25.54, 95% CI: 25.54–85.42, $p < 0.001$) and a one unit increase in experiences of adverse effects of stigma and homophobia (OR = 1.06, 95% CI: 1.01–1.11, $p = 0.044$) were associated with a greater likelihood of receiving the HPV vaccine uptake. Having a greater number of sexual partners (OR = 0.85, 95% CI: 0.75–0.97, $p = 0.014$)
and having had condomless anal sex in the past 6 months (OR = 0.31, 95% CI: 0.15–0.58, p < 0.001) were associated with a lower odds of HPV vaccine uptake. These results are illustrated in Table 3.

**Discussion**

This study is one of few to examine the individual factors that are associated with HPV vaccination among YMSM. Approximately 75.79% (n = 335) of the sample reported that they did not receive at least one dose of the HPV vaccine. This data is consistent with the national observation of low vaccination rates within the YMSM population, indicating a strong need to improve vaccination rates in this population [6, 12, 18]. The strongest predictor of HPV vaccination highlighted in this study was that a lack of healthcare provider recommendations for the HPV vaccine was associated with a decreased likelihood of receiving the vaccine [17]. YMSM study participants who received a provider recommendation to obtain the HPV vaccine were 25 times more likely to receive vaccination uptake. The findings of this study are similar to another study conducted in the same population where a provider recommendation was the single largest predictor of uptake [17]. Although not investigated here, other studies have also found that there is low disclosure of same-sex sexual behavior among MSM [17, 27].

The present study also identified two behavioral indicators that were significant predictors of HPV vaccination among YMSM. These results support similar findings in HIV research that unprotected anal sex is a pervasive behavior that influences both real and perceived risk associated with STI transmission among YMSM [13, 28, 29]. Educational

**Table 2** Characteristics of sexual behaviors and psychosocial factors by HPV vaccination status

| Variable                                    | Vaccination status | Total n (%)/mean (SD) | p value |
|---------------------------------------------|--------------------|-----------------------|---------|
|                                              | Yes  | No              |         |
|                                              | n (%) | n (%)          |         |
|                                              | mean (SD) | mean (SD)      |         |
| Sexual risk behaviors                        |      |                |         |
| # partners                                  | 3.24 (3.65) | 2.23 (1.78)     | 2.5 (2.4) | <0.0001 |
| Age at sexual debut                         | 17.70 (1.93) | 17.78 (1.92)    | 17.78 (1.92) | 0.9734 |
| Condom-less anal sex                        |      |                |         |
| Yes                                         | 80 (36.53) | 139 (63.47)     | 219 (49.66) | <0.0001 |
| No                                          | 27 (12.22) | 194 (87.78)     | 222 (50.34) |         |
| Psychosocial factors                         |      |                |         |
| HPV-related knowledge score                 | 43.89 (7.49) | 44.62 (5.82)    | 44.36 (6.6) | 0.0008 |
| Perceived risk of contracting HPV           | 13.02 (2.54) | 13.02 (2.16)    | 13.02 (2.26) | 0.0361 |
| Attitudes toward HPV and the HPV vaccine    | 28.31 (3.83) | 27.73 (3.79)    | 27.87 (3.81) | 0.8635 |
| Experiences of stigma and homophobia (max: 68) | 48.02 (5.16) | 48.58 (7.10)    | 48.45 (6.68) | 0.0002 |

**Table 3** Multiple logistic regression as predictors of HPV vaccination history

| Variable                                      | OR   | 95% CI LL | 95% CI UL | p value |
|-----------------------------------------------|------|-----------|-----------|---------|
| Income [ref: <$40,000]                        | 1.66 | 0.86      | 3.20      | 0.129   |
| Race/ethnicity [ref: Hispanic/Latino]         |      |           |           |         |
| Non-Hispanic Black                            | 1.63 | 0.57      | 4.67      | 0.078   |
| Non-Hispanic White                            | 0.87 | 0.37      | 2.08      | 0.873   |
| Non-Hispanic other                            | 0.48 | 0.13      | 1.79      | 0.154   |
| Sexual orientation [ref: heterosexual]        |      |           |           |         |
| Gay                                           | 1.64 | 0.55      | 4.88      | 0.397   |
| Bisexual                                      | 1.49 | 0.41      | 5.44      | 0.740   |
| Healthcare provider recommendation [no]       | 25.54| 7.63      | 85.42     | <0.001  |
| Condomless anal sex [no]                      | 0.31 | 0.15      | 0.58      | <0.001  |
| # of sexual partners                          | 0.85 | 0.75      | 0.97      | 0.014   |
| HPV knowledge score                           | 0.98 | 0.93      | 1.03      | 0.409   |
| Adverse effects of stigma and homophobia     | 1.06 | 1.01      | 1.11      | 0.044   |
| Perceived risk of HPV                         | 0.99 | 0.86      | 1.14      | 0.922   |
interventions to promote the HPV vaccine, including sexual health education and other modifiable risk factors, are needed. Philadelphia is one of the poorest major cities and it is crucial to understand how socioeconomic status and financial barriers to vaccine uptake promulgate disparities in vaccine utilization [30]. There is a dearth of information about the average copay or reimbursement for the HPV vaccine. Approximately 77% of study participants who self-reported being uninsured did not receive the vaccine, which implicates the lack of insurance as a barrier to HPV vaccination uptake. The Philadelphia Department of Public Health coordinates the Vaccines for Children (VFC) and Vaccines for Adults at Risk (VFAR) programs which enable providers to provide vaccines to make vaccines available free of charge to children and adults who are uninsured or under-insured [13]. YMSM may be eligible for either of these programs and future interventions could utilize these programs to mitigate financial barriers to vaccine utilization. Future studies should assess the varying health insurance-related barriers to HPV vaccine uptake among the target population.

The present study further identified several important indicators associated with a greater likelihood of individuals receiving the HPV vaccine. The hypothesis of the present study was that psychosocial factors, including experiences of stigma and homophobia, perceived HPV risk, and attitudes toward the HPV vaccine, would be associated with vaccination uptake. However, upon analysis, only a slight unit increase in adverse effects of stigma and homophobia was associated with vaccination status. In addition, education, socioeconomic status, access to primary healthcare providers, and insurance were not associated with HPV vaccination among YMSM. Thus, future interventions that aim to improve HPV vaccination uptake among MSM may require community-level intervention at sexual health clinics and CBOs, in addition to individual-level intervention to improve social norms relating to vaccine utilization [31].

Strengths of the present study include the utilization of a large sample of YMSM in an urban area that was composed of multi-ethnic participants. The cross-sectional design, COVID-19 pandemic, and study duration, however, were study limitations. The COVID-19 pandemic and study duration may have impacted the participation of racial and ethnic minorities who were not connected or affiliated with our recruitment partners at institutions of higher education. Further, the COVID-19 pandemic heavily impacted the participation and daily operations of our local CBOs that served as our recruitment partners. Resultantly, individuals classified as essential workers may have had limited access or awareness of the study. We utilized convenience sampling and patient-driven recruitment strategies targeting YMSM in the Greater Philadelphia region which limits the geographic generalizability of our findings. This study did not control for the potential correlations between psychosocial, sexual behaviors, and healthcare factors. Moreover, this study was not able to capture participants who lack access to technology which may also implicate additional economic barriers to health insurance and access to healthcare. Nor was it possible to identify the specific causation of low HPV vaccination rates in the study population. Participants self-reported vaccination uptake, which may result in undercounting of vaccine utilization.

In conclusion, social, behavioral, financial, and healthcare-related factors place YMSM at a higher risk of contracting HPV [6, 7, 32]. Sexual risk behavior has been shown to be a predictive factor of HPV vaccination uptake. Thus, efforts to increase HPV education and awareness among YMSM are necessary to prevent individuals from contracting this preventable infection. Furthermore, there are opportunities to use behavioral economics strategies to nudge YMSM and healthcare providers to discuss and promote HPV vaccination among YMSM. Additional mixed-methods research is necessary to identify mental models among YMSM regarding vaccination uptake. The present study demonstrates a social norm of low HPV vaccination completion among YMSM in Philadelphia. Our findings underline the importance of healthcare provider recommendations in driving HPV vaccination uptake in the target population. This observation necessitates a population and individual-level intervention that addresses behavioral barriers to HPV uptake by targeting providers and YMSM. Lastly, there is a need to promote LGBTQ specific clinical recommendations for the vaccine through culturally sensitive strategies that address barriers among MSM.

Acknowledgements This research project was supported by grant no. U54 CA221704(5) funded by the National Cancer Institute (NCI) of NIH. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of NCI or NIH. No copyrighted materials or tools were used in this research.

Author Contribution All authors contributed to the study’s conception and design. Material preparation, data collection, and analysis were performed by Tyrell Mann-Barnes, Aisha Bhimla, Ph.D., Timmy Lin, Hemi Park, Michael Coronado, Adebola Duro-Aina, and Grace Ma, Ph.D. The first draft of the manuscript was written by Tyrell Mann-Barnes, Aisha Bhimla, Michael Coronado, Adebola Duro-Aina, and Dr. Ma and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This research project was supported by grant no. U54 CA221704(5) funded by the National Cancer Institute (NCI) of NIH. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of NCI or NIH. No copyrighted materials or tools were used in this research.

Availability of Data and Material Not applicable.

Code Availability Not applicable.
Declarations

Ethics Approval This study was approved by Temple University Institutional Review Board.

Consent to Participate Informed consent was obtained from all individual participants included in the study.

Consent for Publication All participants provided informed consent regarding their data from the study.

Competing Interests The authors declare no competing interests.

References

1. STD facts - human papillomavirus (HPV). 2022 [cited 2022 Feb 21]. Available from: https://www.cdc.gov/std/hpv/stdfact-hpv.htm. Retrieved September 2021.

2. Moscicki A-B, Palefsky JM. Human papillomavirus in men: an update. J Low Genit Tract Dis. 2011;15(3):231–4.

3. What is HPV cancer?. The Anal Cancer Foundation. [cited 2022 Feb 21]. Available from: https://www.analcancerfoundation.org/what-is-anal-cancer/hpv-cancer/. Retrieved September 2021.

4. van Aar F, Mooij SH, van der Sande MAB, Speksnijder AGCL, Stolte IG, Meijer CJLM, et al. Anal and penile high-risk human papillomavirus prevalence in HIV-negative and HIV-infected MSM. AIDS. 2013;27(18):2921–31.

5. IARC. Human papillomaviruses. 2007 [cited 2022 Feb 21]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazar-ds-To-Humans/Human-Papillomaviruses-2007. Retrieved September 2021.

6. Loretan C, Chamberlain AT, Sanchez T, Zlotorzynska M, Jones J. Trends and characteristics associated with human papillomavirus vaccination uptake among men who have sex with men in the United States, 2014–2017. Sex Transm Dis. 2019;46(7):465–73.

7. Cummings T, Kasting ML, Rosenberger JG, Rosenthal SL, Zimet GD, Stupiansky NW. Catching up or missing out? Human papillomavirus vaccine acceptability among 18- to 26-year-old men who have sex with men in a US national sample. Sex Transm Dis. 2015;42(11):601–6.

8. Glick SN, Feng Q, Popov V, Koutsy LA, Golden MR. High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men. J Infect Dis. 2014;209(3):369–76.

9. Goldstone S, Palefsky JM, Giuliano AR, Moreira ED Jr, Aranda C, Jessee H, et al. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis. 2011;203(1):66–74.

10. Patel P, Bush T, Kojic EM, Conley L, Unger ER, Darragh TM, et al. Prevalence, Incidence, and clearance of anal high-risk human papillomavirus infection among HIV-infected men in the SUN study. J Infect Dis. 2018;217(6):953–63.

11. Müller EE, Rebe K, Chirwa TF, Struthers H, McIntyre J, Lewis DA. The prevalence of human papillomavirus infections and associated risk factors in men-who-have-sex-with-men in Cape Town, South Africa. BMC Infect Dis. 2016;16(1):440.

12. Oliver SE, Hoots BE, Paz-Bailey G, Markowitz LE, Meites E, NHBS Study Group. Increasing human papillomavirus vaccine coverage among men who have sex with men-National HIV Behavioral Surveillance, United States, 2014. J Acquir Immune Defic Syndr. 2017;75(Suppl 3):S370–4.

13. Philadelphia Department of Public Health. Philadelphia Immunization Program. 2022. Available from: https://vax.phila.gov/. Retrieved September 2021.

14. HPV vaccination: what everyone should know | CDC. 2022 [cited 2022 Feb 21]. Available from: https://www.cdc.gov/vaccines/vpd/hpv/public/index.html. Retrieved September 2021.

15. Meites E. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019 [cited 2022 Feb 21]:68. Available from: https://www.cdc.gov/mmwr/volumes/68/wr/mm68032a3.htm. Retrieved September 2021

16. ACIP HPV vaccine recommendations | CDC. 2019 [cited 2022 Feb 21]. Available from: https://www.cdc.gov/vaccines/hcp/acip-reccs/vacc-specific/hpv.html. Retrieved September 2021.

17. Gerend MA, Madkins K, Phillips G, Mustanski B. Predictors of human papillomavirus vaccination among young men who have sex with men. Sex Transm Dis. 2016;43(3):185–91.

18. McClung N, Burnett J, Wejnert C, Markowitz LE, Meites E. Human papillomavirus vaccination coverage among men who have sex with men—National HIV Behavioral Surveillance, United States, 2017. Vaccine. 2020;38(47):7417–21.

19. McKirnan DJ, Du Bois SN, Alvy LM, Jones K. Health care access and health behaviors among men who have sex with men: the cost of health disparities. Health Educ Behav. 2013;40(1):32–41.

20. Nadarzynski T, Smith H, Richardson D, Jones CJ, Llewellyn CD. Human papillomavirus and vaccine-related perceptions among men who have sex with men: a systematic review. Sex Transm Infect. 2014;90(7):515–23.

21. Wheldon CW, Daley EM, Walsh-Buhi ER, Baldwin JA, Nyitray AG, Giuliano AR. An integrative theoretical framework for HPV vaccine promotion among male sexual minorities. Am J Mens Health. 2018;12(5):1409–20.

22. Fontenot HB, Fantasia HC, Vetters R, Zimet GD. Increasing HPV vaccination and eliminating barriers: recommendations from young men who have sex with men. Vaccine. 2016;34(50):6209–16.

23. Finneran C, Johnson Peretz J, BLEMUR D, PALEFSKY J, FLOW- ers L. “That’s only for women”: the importance of educating HIV-positive sexual minority men on HPV and high resolution anoscopy (HRA). J Int Assoc Provid AIDS Care. 2021;20:23259582211016136.

24. Wheldon CW, Daley EM, BUHI ER, Nyitray AG, Giuliano AR. Health beliefs and attitudes associated with HPV vaccine intention among young gay and bisexual men in the Southeastern United States. Vaccine. 2011;29(45):8060–5.

25. Haupert ML. Considerations for the development and implementation of transgender–inclusive gender demographic questions. 2019. https://scholarworks.iu.edu/dspace/handle/2022/22925. Accessed 15 August 2021.

26. Forster AS, McBride KA, Davies C, Stoney T, Marshall H, McGeechan K, et al. Development and validation of measures to evaluate adolescents’ knowledge about human papillomavirus (HPV), involvement in HPV vaccine decision-making, self-efficacy to receive the vaccine and fear and anxiety. Public Health. 2017;147:77–83.

27. Gorbach PM, Cook R, Gratzer B, Collins T, Parrish A, Moore J, et al. Human papillomavirus vaccination among young men who have sex with men and transgender women in 2 US cities, 2012–2014. Sex Transm Dis. 2017;44(7):436–41.

28. Johnson WD, Holtgrave DR, McClellan WM, Flanders WD, Hill AN, Goodman M. HIV intervention research for men who have sex with men: a 7-year update. Database of Abstracts of Reviews of Effects (DARE): quality-assessed reviews. Centre for Reviews and Dissemination (UK); 2005 [cited 2022 Feb 21]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK72042/
29. Lauby J, Zhu L, Milnamow M, Batson H, Bond L, Curran-Groome W, et al. Get real: evaluation of a community-level HIV prevention intervention for young MSM who engage in episodic substance use. AIDS Educ Prev. 2017;1(29):191–204.

30. Shields M. The changing distribution of poverty in Philadelphia. The Economy League: Greater Philadelphia. Available from: https://economyleague.org/providing-insight/leadingindicators/2020/12/16/phipv19. Retrieved September 2021.

31. King EM, Gilson R, Beddo ws S, et al. Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. Br J Cancer. 2015;112(9):1585–93. https://doi.org/10.1038/bjc.2015.90.

32. Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, Jin T. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. Front Public Health. 2021;1003. https://www.frontiersin.org/articles/10.3389/fpubh.2020.552028/full.

33. Crosby RA, Sanders SA, Graham CA, Milhausen R, Yarber WL, Mena L. Evaluation of the condom barriers scale for young Black men who have sex with men: reliability and validity of 3 subscales. Sex Transm Dis. 2017;44(2):91–5.

Publisher’s Note Springer Nature remains neutral with regard to jurisdicational claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.